newsroom/
12 pages · Updated September 7, 2026
Pages
- Medable and ICON Exceed Patient eConsent Adoption Goals for Women’s Health Study on Menopause | Medable
- New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI | Medable
- Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing | Medable
- Medable Launches The Industry’s First Agentic AI Platform and CRA Agent; Removes Bottlenecks in Clinical Development | Medable
- Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access | Medable
- Medable Introduces Digital Data Flow Agent, Laying the Foundation for End-to-End Agentic Clinical Development | Medable
- Medable Debuts AI Agent for Automating Trial Master File (TMF) Processes | Medable
- Medable Named a Leader Amid Growing eCOA Adoption | Medable
- Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers | Medable
- Medable Launches Agentic Accelerator Program to Help Life Sciences Companies Deploy Agentic AI Across Clinical Development Lifecycle | Medable
- Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices | Medable
- Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union | Medable